--- title: "U.S. stock market midday update: Phio Pharmaceuticals down 10.31%, trading volume increased, market sentiment fluctuations attract attention" type: "News" locale: "en" url: "https://longbridge.com/en/news/276164345.md" description: "Phio Pharmaceuticals fell 10.31%; AbbVie rose 0.57%, with a transaction volume of USD 952 million; Gilead Sciences fell 0.18%, with a transaction volume of USD 548 million; Amgen rose 1.02%, with a transaction volume of USD 489 million; Vertex Pharmaceuticals fell 3.28%, with a market value of USD 120.8 billion" datetime: "2026-02-17T20:27:37.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/276164345.md) - [en](https://longbridge.com/en/news/276164345.md) - [zh-HK](https://longbridge.com/zh-HK/news/276164345.md) --- # U.S. stock market midday update: Phio Pharmaceuticals down 10.31%, trading volume increased, market sentiment fluctuations attract attention **U.S. Stock Market Midday Update** Phio Pharmaceuticals fell 10.31%, with increased trading volume and no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. **Stocks with High Trading Volume in the Industry** AbbVie rose 0.57%. Based on recent news, 1. On February 16, MarketBeat reported that although AbbVie currently has a moderate buy rating among analysts, top analysts believe there are five stocks that are more worthy of investment than AbbVie. This news may lead some investors to reassess their positions, affecting the stock price. 2. On February 15, The Motley Fool analyst team pointed out that AbbVie is one of the top choices for long-term income investors, especially after the recent decline in stock price. This viewpoint may have boosted market confidence, driving the stock price up. 3. On February 15, MarketBeat reiterated that despite AbbVie having a moderate buy rating, top analysts are more optimistic about five other stocks. This repeated report may further influence investor sentiment. The overall market performance is stable, with significant capital inflow. Gilead Sciences fell 0.18%. Based on recent key news: 1. On February 18, Gilead Sciences announced the acquisition of global exclusive rights to the MAT2A inhibitor GH31 from Suzhou Genhouse Bio for $80 million. This move aims to expand its oncology treatment product line and may have a positive impact on the stock price. Source: Business Wire 2. On February 17, Gilead Sciences released safety information regarding Yeztugo, emphasizing precautions for its use in undiagnosed HIV-1 infections. Such information may raise market concerns about the safety of its products. Source: Business Wire 3. On February 16, MarketsandMarkets™ launched an AI-driven sales intelligence tool aimed at helping businesses identify market opportunities. Although not directly related to Gilead Sciences, it shows the market's focus on technological innovation. Source: MarketsandMarkets™ The competition in the oncology treatment field is intensifying, and policy changes need to be monitored. Amgen rose 1.02%. Based on recent news, 1. On February 18, Amgen released strong growth expectations for the nutrition and beauty market. With the focus on beauty trends, preventive health care, and accelerated ingredient innovation, the demand for nutrition and beauty products has significantly increased. This news boosted investor confidence, driving Amgen's stock price up. 2. Recently, Amgen has made significant progress in innovation and research and development across multiple fields, particularly in biopharmaceuticals and gene therapy. These advancements have enhanced market expectations for the company's future growth, further driving the stock price up 3. Analysts are generally optimistic about Amgen's long-term development prospects, and recently several investment banks have raised their ratings and target prices for Amgen. These positive rating changes have also supported the stock price. The biopharmaceutical industry has performed strongly recently, with significant capital inflows. **Stocks ranked among the top in industry market capitalization** Forte Pharmaceuticals fell 3.28%. Based on recent key news: 1. On February 16, Cornerstone Pharmaceuticals announced that its core asset CS2009's Phase II clinical trial application was approved by the FDA. This news has increased market attention on innovative drugs, which may affect Forte Pharmaceuticals' market competitiveness. 2. On February 17, Deciphera Pharmaceuticals announced that the FDA accepted its new drug application, setting the PDUFA date for December 18, 2026. The progress of drug development in this area may impact Forte Pharmaceuticals' market position. 3. On February 17, Vertex Pharmaceuticals' target price was raised to $607 by Barclays. Analysts' positive ratings for other companies in the industry may influence investor confidence in Forte Pharmaceuticals. The pharmaceutical industry's innovative drug development is active, and competition is intensifying ### Related Stocks - [PHIO.US](https://longbridge.com/en/quote/PHIO.US.md) ## Related News & Research - [Incyte Corporation $INCY Holdings Lowered by Massachusetts Financial Services Co. MA](https://longbridge.com/en/news/282969492.md) - [Is Coca‑Cola (KO) Offering Value After Recent Share Price Softness?](https://longbridge.com/en/news/282976703.md) - [Kelsey Financial LLC Makes New $7.13 Million Investment in Amgen Inc. $AMGN](https://longbridge.com/en/news/282444235.md) - [Psyence Biomedical Expands Australian Psilocybin Trial Network to Five Sites](https://longbridge.com/en/news/282826714.md) - [New Deloitte Study Shows that AI-powered Agreement Management Is Paying Off | DOCU Stock News](https://longbridge.com/en/news/283023421.md)